Skip to content

Monday, March 8, 2021

Latest:

Mount Sinai Launches Program to Increase Black Women Leaders in Executive Roles
FSU EXPERTS AVAILABLE TO LOOK BACK ON PAST YEAR WITH COVID-19
From local to global, Argonne initiatives drive gender equality, diversity, respect
Cohen Veterans Bioscience And The European College Of Neuropsychopharmacology Announce The 2021 Best Negative Data Prize In Clinical Neuroscience
Maxine Clark: The curious entrepreneur

sciencenewsnet.in

news, journals and articles from all over the world.

Home
Research Results
Uncategorized
DOE Science News
Privacy Policy
Contact us
English

Arabic Chinese (Simplified) Dutch English French German Italian Korean Portuguese Russian Spanish

metastatic pancreatic ductal carcinoma

Research Results

New Research in JNCCN Evaluates Cost-Effectiveness of Olaparib, a PARP Inhibitor, for Metastatic Pancreatic Cancer

November 11, 2020 sarah Jonas Cost Effectiveness, jnccn, JNCCN - Journal of the National Comprehensive Cancer Network, Metastatic Pancreatic Cancer, metastatic pancreatic ductal carcinoma, National Comprehensive Cancer Network, NCCN, Pancreatic Cancer, Pancreatic Cancer Awareness Month, PARP inhibitors, Qaly

New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.

Read more

Copyright © 2021 sciencenewsnet.in. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.